TY - JOUR T1 - Impact of chronic Achilles tendinopathy on health-related quality of life, work performance, healthcare utilisation and costs JF - BMJ Open Sport & Exercise Medicine JO - BMJ OPEN SP EX MED DO - 10.1136/bmjsem-2020-001023 VL - 7 IS - 1 SP - e001023 AU - Tjerk S O Sleeswijk Visser AU - Arco C van der Vlist AU - Robert F van Oosterom AU - Peter van Veldhoven AU - Jan A N Verhaar AU - Robert-Jan de Vos Y1 - 2021/03/01 UR - http://bmjopensem.bmj.com/content/7/1/e001023.abstract N2 - Objectives To evaluate the impact of Achilles tendinopathy (AT) on quality of life (QoL), work performance, healthcare utilisation and costs in adults with conservatively treated chronic midportion AT.Methods This cross-sectional survey-based study included 80 patients and took place in a sports medicine department of a large regional hospital in the Netherlands. Data were collected before any intervention was given. Primary outcome was the EuroQol questionnaire (EQ-5D). The EQ-5D expresses the percentage of moderate/major problems on the domains self-care, anxiety/depression, mobility, usual activities and pain/discomfort. Secondary outcomes were the number of previous healthcare visits, work performance during the period of symptoms and estimated annual direct medical and indirect costs per patient as a result of AT.Results All 80 patients completed the questionnaires. The EQ-5D scores were low for the domains self-care (1%) and anxiety/depression (20%), and high for the domains mobility (66%), usual activities (50%) and pain/discomfort (89%). Patients with AT mainly reported an impact on work productivity (38%). Work absenteeism due to AT was present in 9%. The total median (IQR) number of annual healthcare visits was 9 (3–11). The total mean (SD) estimated annual costs were €840 (1420) per patient with AT (mean (SD) US$991 (1675)).Conclusions This study shows the large impact of AT on QoL and work productivity. This study also provides new information about the socioeconomic impact of AT, which emphasises that this common and longstanding disease causes substantial costs. These findings stress the need for optimised treatment and improved preventive interventions for AT.Trial registration number NCT02996409. ER -